Talaporfin
As of the edition of 20 October 2026, Talaporfin is a small molecule: marketed, first approved in 2003 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Laserphyrin
- First approved
- 26 October 2003 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Meiji Seika Pharm; 2 holders in all
- Registered trials
- 11, 1 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Skin and connective tissue; Blood and lymph; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Meiji Seika Pharma | Applicant |